Vigilant Biosciences' OncAlert oral cancer CD44/total protein lab test has received the CE Mark, which allows the company to market the test in Europe.
The test can now be sold in the 28 countries of the European Union, as well as Norway, Iceland, Liechtenstein, and Switzerland. The OncAlert system is not available in the U.S. at this time, the company said.
The assay detects a tumor-initiating stem cell biomarker for head and neck cancer, Vigilant said. It measures soluble CD44 and total protein levels -- specific protein markers known to indicate early-stage cancers -- in an oral rinse.
